Applied Biosystems Announces Launch of Micro Fluidic Card for Parallel, High Throughput Gene Expression Analysis
FOSTER CITY, Calif., May 13, 2003 (BUSINESS WIRE) -- Applied
Biosystems Group (NYSE:ABI), an Applera Corporation business, today
introduced the Applied Biosystems 7900HT Micro Fluidic Card, an assay
system designed for customization with the Applied Biosystems
Assays-on-Demand(TM) Gene Expression Products for use on the ABI PRISM
(R)7900HT Sequence Detection System.
The Applied Biosystems 7900HT Micro Fluidic Card allows high
throughput, parallel analysis of gene expression patterns, and is
expected to expedite customers' target discovery programs by allowing
researchers to investigate complex biological pathways more quickly
and cost-effectively. The 7900HT Micro Fluidic Card is designed for
custom configuration using the Applied Biosystems Assays-on-Demand(TM)
Gene Expression Products for both human and mouse genes. Customers can
create their own micro card configuration online by selecting from
over 26,000 Applied Biosystems Assays-on-Demand(TM) Gene Expression
Products, which include more than 18,000 gene-specific assays for
human genes and over 8,000 gene-specific assays for mouse genes.
"Real-Time PCR using TaqMan(R) probes is a very precise analytical
method for the analysis of gene expression. The 7900HT Micro Fluidic
Card represents another advance in gene expression technologies from
Applied Biosystems that should allow customers to take advantage of
this gold standard technology, not only for examining one or a few
genes but even tens to hundreds of genes at a time," said Michael W.
Hunkapiller, Ph.D., President of Applied Biosystems. "As a result,
scientists can look at larger collections of genes to ultimately
better understand the pathways and networks involved in complex
The Applied Biosystems 7900HT Micro Fluidic Card can be ordered
through the recently enhanced Applied Biosystems e-commerce site at
http://store.appliedbiosystems.com/. The 7900HT Micro Fluidic Card is
a micro reaction vessel system that supports up to 10 different
configuration options with 12-384 assays per card. Interested parties
may browse the online catalog of assays free of charge. The 7900HT
Micro Fluidic Card was developed in partnership with 3M of St. Paul,
Minnesota through a collaboration formed in 1999. The collaboration
combines 3M's strengths in material science and manufacturing with
Applied Biosystems' strengths in genetic analysis science and
About Applera Corporation and Applied Biosystems
Applera Corporation comprises two operating groups. The Applied
Biosystems Group develops and markets instrument-based systems,
reagents, software, and contract services to the life science industry
and research community. Customers use these tools to analyze nucleic
acids (DNA and RNA), small molecules, and proteins to make scientific
discoveries, develop new pharmaceuticals, and conduct standardized
testing. Applied Biosystems is headquartered in Foster City, CA, and
reported sales of $1.6 billion during fiscal 2002. The Celera Genomics
Group (NYSE:CRA), located in Rockville, MD, and South San Francisco,
CA, is engaged principally in integrating advanced technologies to
discover and develop new therapeutics. Celera intends to leverage its
proteomic, bioinformatic, and genomic capabilities to identify and
validate drug targets, and to discover and develop new therapeutics.
Its Celera Discovery System(TM) online platform, marketed exclusively
through the Applied Biosystems Knowledge Business, is an integrated
source of information based on the human genome and other biological
and medical sources. Celera Diagnostics, a 50/50 joint venture between
Applied Biosystems and Celera Genomics, is focused on discovery,
development, and commercialization of novel diagnostic products.
Information about Applera Corporation, including reports and other
information filed by the company with the Securities and Exchange
Commission, is available at http://www.applera.com, or by telephoning
800.762.6923. Information about Applied Biosystems is available at
Certain statements in this press release are forward-looking.
These may be identified by the use of forward-looking words or phrases
such as "should" and "expect," among others. These forward-looking
statements are based on Applera Corporation's current expectations.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for such forward-looking statements. In order to comply with
the terms of the safe harbor, Applera Corporation notes that a variety
of factors could cause actual results and experience to differ
materially from the anticipated results or other expectations
expressed in such forward-looking statements. These factors include
but are not limited to (1) sales dependent on customers' capital
spending policies and government-sponsored research; (2) Applied
Biosystems' dependence on the operation of computer hardware,
software, and Internet applications and related technology; (3)
unproven use of genomics information to develop or commercialize
products; (4) rapidly changing technology and dependence on
development of new products and; (5) other factors that might be
described from time to time in Applera Corporation's filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Applera does not
undertake any duty to update this information, including any
forward-looking statements, unless required by law.
For Research Use Only. Not for use in diagnostic procedures.
ABI PRISM and Applied Biosystems are a registered trademarks and
AB (Design), Applera, Assays-on-Demand, Celera, Celera Discovery
System, and Celera Genomics are trademarks of Applera Corporation
and/or its subsidiaries in the U.S. and certain other countries.
TaqMan is a registered trademark of Roche Molecular Systems, Inc.
The PCR process and 5' nuclease process are covered by patents
owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd.
The Micro Fluidic Card was developed in collaboration with 3M
SOURCE: Applied Biosystems Group
Lori Murray, 650/638-6130 (Media)
Linda Greub, 650/554-2349 (Investors)
David Speechly, Ph.D., (+) 44 207-868-2012
(European Media & Investors)